bioRxivSynthetic BiologyPreprint
Protein design to broadly reprogram engineered T cell function
Scott E. BoykeniD, Sean Merillat, Robert A. LanganiD, Howell F. MoffettiD, Brian CoventryiD, Françoise HaeseleeriD, Kevin G. HaworthiD, Inna GoreshnikiD, Joseph DeSautelle, John Chukinas, Bradley HammersoniD, Thaddeus M. DavenportiD, Duy Nguyen, Rupesh H. Amin, Shujun Yuan, G. WinkiD, Brian D. WeitzneriD, Aaron Edward FosteriD, David A. BakeriD, Marc J. LajoieiD
- Citations
- 0
Abstract
The efficacy of engineered T cell therapies in solid tumors remains limited by T cell dysfunction, driven by complex processes that cannot be easily manipulated via genetic knockouts or overexpression of individual genes. Protein design can create new biological functions that can rewire these consequential cell fate decisions. Here, we introduce OUTLAST Regulators, designed proteins that reprogram critical T cell signaling pathways to enhance functional persistence. These proteins are capable of regulating diverse groups of proteins such as the NR4A family of pro-exhaustion transcription factors, E3 ligases Cbl-b and c-Cbl, and SOCS family proteins. Our designs markedly improve CAR-T and TCR-T performance in vitro and in vivo in stringent solid tumor preclinical models. OUTLAST Regulators are implemented as compact genetic modules compatible with standard viral vectors and cell therapy manufacturing processes, creating a powerful platform for programming new functions into enhanced cell and gene therapies.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Reprogramming CAR T-Cells with designed bioPROTACs
Vivek S. Peche, Sebastian Kenny, … Stephen M Gottschalk·bioRxiv·Feb 22, 2026
- A Rationally Designed Transgene Drives CAR T Functional Persistence and Durable Regression of Solid Tumors
Rupesh H. Amin, Kevin G. Haworth, … Aaron Edward Foster·bioRxiv·Sep 24, 2026
- Rational Tuning of CAR Tonic Signaling Yields Superior T-Cell Therapy for Cancer
X. Chen, M. Khericha, … Y. Y. Chen·bioRxiv·Oct 1, 2020
- Design of novel synthetic promoters to tune gene expression in T cells
Giuliano Bonfá, Giovanna Martino, … Velia Siciliano·bioRxiv·Jan 9, 2025
- Reversible control of T cell exhaustion by NR4A transcription factors revealed through targeted protein degradation
Erik Ehinger, Kristy C. Perez, … Patrick G. Hogan·bioRxiv·Feb 4, 2026
- Solid tumor CAR T cells engineered with fusion proteins targeting PDL1 for localized IL-12 delivery
John Paul Murad, Lea Christian, … Saul J. Priceman·bioRxiv·Apr 4, 2025